JENBURKT PHARMACEUTICAL L Latest Share Price (JENBURPH)
TODAY IN ONE LINE
JENBURPH slipped 0.3%, lagging Nifty's 2.0% move.
With a market cap of ₹416.17 Cr., it trades at a P/E of 12.31. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
JENBURKT PHARMACEUTICAL L flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Steady Dividend YieldReliable 2.20% dividend yield
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
No red flags identified
Latest JENBURKT PHARMACEUTICAL L News
What changed recently?
Recent events, corporate actions, and announcements.
JENBURKT PHARMACEUTICAL L valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for JENBURKT PHARMACEUTICAL L, framed against the sector median so the premium or discount is obvious at a glance.
JENBURKT PHARMACEUTICAL L trades at a P/E of 12.31× and P/B of 2.05×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
JENBURKT PHARMACEUTICAL L technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for JENBURKT PHARMACEUTICAL L — derived from the latest tape, not yesterday's close.
JENBURKT PHARMACEUTICAL L last traded at ₹940.95 with an intraday range of ₹917.6–₹948.4 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹940.95| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1015.30 | +74.35 | +7.90% |
| R3 | 984.50 | +43.55 | +4.63% |
| R2 | 966.45 | +25.50 | +2.71% |
| R1 | 953.70 | +12.75 | +1.36% |
| PIVOT | 935.65 | -5.30 | -0.56% |
| CURRENT | 940.95 | — | — |
| S1 | 922.90 | -18.05 | -1.92% |
| S2 | 904.85 | -36.10 | -3.84% |
| S3 | 892.10 | -48.85 | -5.19% |
| S4 | 861.30 | -79.65 | -8.46% |
JENBURPH is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹940.25–₹950
Trading Inside opening range
JENBURKT PHARMACEUTICAL L financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for JENBURKT PHARMACEUTICAL L — consolidated or standalone — with margins, YoY growth and key ratios inline.
JENBURKT PHARMACEUTICAL L reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹416.17 Cr. and reported EPS of ₹13.34.
JENBURKT PHARMACEUTICAL L segment analysis : revenue and profit mix.
Disclosed business segments at JENBURKT PHARMACEUTICAL L with their share of revenue and profit, switchable between consolidated and standalone reporting.
JENBURKT PHARMACEUTICAL L discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for JENBURKT PHARMACEUTICAL L.
Our AI distills the core fundamental drivers supporting JENBURKT PHARMACEUTICAL L, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
What you're getting.
No strengths or opportunities on record.
Key Risks.
No weaknesses or threats on record.
Flip Conditions.
Valuation risk. a P/E above 16 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Income thesis breaks if the dividend is cut or yield falls below 1.10%.
JENBURKT PHARMACEUTICAL L peer comparison — same-sector benchmarks.
No comparable peer set was disclosed for JENBURKT PHARMACEUTICAL L.
Peer comparison data is not available.
JENBURKT PHARMACEUTICAL L chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for JENBURKT PHARMACEUTICAL L — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
JENBURKT PHARMACEUTICAL L delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for JENBURKT PHARMACEUTICAL L over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in JENBURKT PHARMACEUTICAL L stood at 58.9% of traded volume, against a 20-day average of 81.9%.
JENBURKT PHARMACEUTICAL L announcements: results, concalls, ratings, M&A.
Filings JENBURKT PHARMACEUTICAL L sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
JENBURKT PHARMACEUTICAL L files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 25 documents below.
Company Update
Intimation regarding admission of Equity shares of the Company under " Permitted to trade" category on National Stock Exchange of India Limited.
Insider Trading / SAST
Intimation of closure of trading window of the Jenburkt Pharmaceuticals Limited as per the SEBI(Prohibition of Insider Trading) Regulations, 2015.
Company Update
Intimation about Resignation of a Senior Management Personnel of the Company.
Company Update
Re-Appointment of Shri. Dilip H. Bhuta (DIN 01357252) as Whole Time Director and CFO of the Company for the Period of 05 years from 01st April, 2027…
AGM/EGM
Submission of consolidated Voting Results and Scrutinizer''s Report on all the Resolutions as set out in the Notice Convening the 41st AGM of the…
JENBURKT PHARMACEUTICAL L dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue JENBURKT PHARMACEUTICAL L has declared, sequenced by announce and record date.
JENBURKT PHARMACEUTICAL L corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About JENBURKT PHARMACEUTICAL L: business, sector, key facts.
What JENBURKT PHARMACEUTICAL L does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
JENBURKT PHARMACEUTICAL L is a listed Indian equity.
JENBURKT PHARMACEUTICAL L
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
Questions investors ask about JENBURKT PHARMACEUTICAL L (JENBURPH).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of JENBURKT PHARMACEUTICAL L (JENBURPH)?
The current share price of JENBURKT PHARMACEUTICAL L (JENBURPH) is ₹940.95. Today, the stock has declined by ₹3.05 (0.32%), trading in a range of ₹917.60 to ₹948.40. The stock opened at ₹917.60 with a trading volume of 207 shares.
02Is JENBURKT PHARMACEUTICAL L stock a good investment for long-term?
JENBURKT PHARMACEUTICAL L can be considered for long-term investment based on several factors. The company has a market capitalization of ₹416.17 Cr., P/E ratio of 12.31, ROE of 0%, and ROCE of 0%. The dividend yield stands at 2.2%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of JENBURKT PHARMACEUTICAL L stock?
The 52-week high price of JENBURKT PHARMACEUTICAL L (JENBURPH) is ₹1,073.90, while the 52-week low is ₹845.00. Currently trading at ₹940.95, the stock is 11.36% above its 52-week low and 12.38% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy JENBURKT PHARMACEUTICAL L stock at the current price?
Whether to buy JENBURKT PHARMACEUTICAL L stock at ₹940.95 depends on multiple factors. The stock is currently trading with a P/E ratio of 12.31 and P/B ratio of 2.05. Today's performance shows a loss of 0.32%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of JENBURKT PHARMACEUTICAL L and when is the next dividend?
JENBURKT PHARMACEUTICAL L offers a dividend yield of 2.2%, which means for every ₹100 invested at the current price of ₹940.95, you can expect to receive approximately ₹2.20 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06How is JENBURKT PHARMACEUTICAL L stock performing today in the market?
JENBURKT PHARMACEUTICAL L stock opened at ₹917.60 and is currently trading at ₹940.95, showing a decline of ₹3.05 (0.32%). The intraday high is ₹948.40 and low is ₹917.60. The trading volume stands at 207 shares, indicating moderate market participation today.
07What is the P/E ratio of JENBURKT PHARMACEUTICAL L and what does it indicate?
JENBURKT PHARMACEUTICAL L has a Price-to-Earnings (P/E) ratio of 12.31, which means investors are willing to pay 12.31 for every ₹1 of earnings. With an EPS of ₹13.34, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
08What is the market capitalization of JENBURKT PHARMACEUTICAL L?
JENBURKT PHARMACEUTICAL L has a market capitalization of ₹416.17 Cr., making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹940.95) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
The data, ratios and commentary about JENBURKT PHARMACEUTICAL L (JENBURPH) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.